Literature DB >> 22157869

Endogenous opioids as physiological antidepressants: complementary role of δ receptors and dopamine.

Emily M Jutkiewicz1, Bernard P Roques.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22157869      PMCID： PMC3238090          DOI： 10.1038/npp.2011.244

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  9 in total

1.  Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses.

Authors:  D Filliol; S Ghozland; J Chluba; M Martin; H W Matthes; F Simonin; K Befort; C Gavériaux-Ruff; A Dierich; M LeMeur; O Valverde; R Maldonado; B L Kieffer
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

2.  Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment.

Authors:  L Cordonnier; M Sanchez; B P Roques; F Noble
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors.

Authors:  M Mas Nieto; S L E Guen; B L Kieffer; B P Roques; F Noble
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

Review 4.  The antidepressant -like effects of delta-opioid receptor agonists.

Authors:  Emily M Jutkiewicz
Journal:  Mol Interv       Date:  2006-06

Review 5.  Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs.

Authors:  Florence Noble; Bernard P Roques
Journal:  Expert Opin Ther Targets       Date:  2007-02       Impact factor: 6.902

6.  Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women.

Authors:  Susan E Kennedy; Robert A Koeppe; Elizabeth A Young; Jon-Kar Zubieta
Journal:  Arch Gen Psychiatry       Date:  2006-11

7.  Altered striatal activation predicting real-world positive affect in adolescent major depressive disorder.

Authors:  Erika E Forbes; Ahmad R Hariri; Samantha L Martin; Jennifer S Silk; Donna L Moyles; Patrick M Fisher; Sarah M Brown; Neal D Ryan; Boris Birmaher; David A Axelson; Ronald E Dahl
Journal:  Am J Psychiatry       Date:  2008-12-01       Impact factor: 18.112

8.  The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat striatum.

Authors:  Kelly E Bosse; Emily M Jutkiewicz; Margaret E Gnegy; John R Traynor
Journal:  Neuropharmacology       Date:  2008-06-18       Impact factor: 5.250

9.  Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses.

Authors:  David J Scott; Christian S Stohler; Christine M Egnatuk; Heng Wang; Robert A Koeppe; Jon-Kar Zubieta
Journal:  Arch Gen Psychiatry       Date:  2008-02
  9 in total
  8 in total

Review 1.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Authors:  Bernard P Roques; Marie-Claude Fournié-Zaluski; Michel Wurm
Journal:  Nat Rev Drug Discov       Date:  2012-04       Impact factor: 84.694

2.  Suicidal ideation in depressed postpartum women: Associations with childhood trauma, sleep disturbance and anxiety.

Authors:  Dorothy Sit; James Luther; Daniel Buysse; John L Dills; Heather Eng; Michele Okun; Stephen Wisniewski; Katherine L Wisner
Journal:  J Psychiatr Res       Date:  2015-05-05       Impact factor: 4.791

3.  Asymmetry of the endogenous opioid system in the human anterior cingulate: a putative molecular basis for lateralization of emotions and pain.

Authors:  Hiroyuki Watanabe; Sylvia Fitting; Muhammad Z Hussain; Olga Kononenko; Anna Iatsyshyna; Takashi Yoshitake; Jan Kehr; Kanar Alkass; Henrik Druid; Henrik Wadensten; Per E Andren; Ingrid Nylander; Douglas H Wedell; Oleg Krishtal; Kurt F Hauser; Fred Nyberg; Victor M Karpyak; Tatjana Yakovleva; Georgy Bakalkin
Journal:  Cereb Cortex       Date:  2013-08-19       Impact factor: 5.357

Review 4.  Mechanisms of the placebo effect in pain and psychiatric disorders.

Authors:  R D Holmes; A K Tiwari; J L Kennedy
Journal:  Pharmacogenomics J       Date:  2016-03-22       Impact factor: 3.550

Review 5.  Advances in novel molecular targets for antidepressants.

Authors:  Qingzhong Wang; Yogesh Dwivedi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-07-16       Impact factor: 5.067

6.  Temporal regulation of peripheral BDNF levels during cocaine and morphine withdrawal: comparison with a natural reward.

Authors:  Hélène Anne-Sophie Geoffroy; Stephanie Puig; Nadia Benturquia; Florence Noble
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-07       Impact factor: 5.176

7.  Antidepressant Potentials of Components from Trichilia monadelpha (Thonn.) J.J. de Wilde in Murine Models.

Authors:  Kennedy Kwami Edem Kukuia; Jeffrey Amoako Mensah; Patrick Amoateng; Seth Kwabena Amponsah; Benoit Banga N'Guessan; Isaac Julius Asiedu-Gyekye
Journal:  Evid Based Complement Alternat Med       Date:  2018-04-22       Impact factor: 2.629

Review 8.  The role of enkephalinergic systems in substance use disorders.

Authors:  Lauren G Rysztak; Emily M Jutkiewicz
Journal:  Front Syst Neurosci       Date:  2022-08-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.